Global Circulating Tumor Cells (CTC) Liquid Biopsy Market - Industry Trends and Forecast to 2029
- Published Date: 2022-11-22
- Report ID: 144299
- Pages: 200
-
Format:
Short Description
Global Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerlands, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of Middle East and Africa) - Industry Trends and Forecast -2029
Market Definition:
The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites. It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.
The circulating tumor cells are a rare sub-set of cells which function as a seed of metastases. It is found in blood of patients who have developed solid tumors. The testing of circulating tumor cells allows the detection and quantification of tumor cells in the blood of cancer patients. The various types of biological phenotypes of circulating tumor cells (CTCs) exits includes stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity. Due to which, their detection needs a phase of isolation-enrichment. After that, a second phase of detection.
Market Segmentation:
The global circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user.
On the basis of technology, global circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies
On the basis of application, global circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others
On the basis of end user, global circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories
Market Players
The major companies which are dealing in the global circulating tumor cells (CTC) liquid biopsy market are listed below:
Eurofins Genomics ( a subsidiary of Eurofins Scientific)
MDx Health
Guardant Health
IMMUCOR
Thermo Fisher Scientific, Inc.
Menarini Silicon Biosystems
QIAGEN
Exact Sciences Corporation
Myriad Genetics, Inc.
LungLife AI, Inc.
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Natera Inc.
ExoDx ( a subsidiary of Bio-Techne Corporation)
Biocept, Inc.
F. Hoffman-La Roche Ltd.
FOUNDATION MEDICINE, INC.
Lucence Health, Inc.
Inivata Ltd
Biolidics Limited
Vortex Biosciences
TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 21
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 31
2.7 TECHNOLOGY LIFELINE CURVE 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET APPLICATION COVERAGE GRID 34
2.11 VENDOR SHARE ANALYSIS 35
2.12 SECONDARY SOURCES 36
2.13 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 39
4.1 PESTEL ANALYSIS 40
4.2 PORTERS FIVE FORCES 41
5 REGULATIONS: GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 44
5.1 ROLE OF FDA 44
5.2 ROLE OF CDC AND HCFA 44
6 MARKET OVERVIEW 46
6.1 DRIVERS 48
6.1.1 HIGH PREVALENCE OF CANCER 48
6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY 49
6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER 50
6.1.4 RISE IN FDA APPROVAL 50
6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY 51
6.2 RESTRAINTS 51
6.2.1 DOWNSIDES OF LIQUID BIOPSY 51
6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING 51
6.3 OPPORTUNITIES 52
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 52
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 52
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 53
6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES 54
6.4 CHALLENGES 54
6.4.1 SHORTAGE OF SKILLED PERSONNEL 54
6.4.2 LACK OF ACCESSIBILITY 55
7 COVID-19 IMPACT ON GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 56
7.1 IMPACT ON PRICE 56
7.2 IMPACT ON DEMAND 56
7.3 IMPACT ON SUPPLY 56
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19 57
7.5 CONCLUSION: 57
8 GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY 58
8.1 OVERVIEW 59
8.2 CTC DETECTION METHODS 62
8.3 CTC ENRICHMENT METHODS 62
8.4 EX VIVO POSITIVE SELECTION 63
8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES 63
8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY 64
8.7 XENOTRANSPLANTATION MODELS 65
8.8 MICROCHIPS 65
8.9 SINGLE SPIRAL MICROCHANNEL 66
8.10 NEGATIVE SELECTION 67
8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES 68
9 GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION 69
9.1 OVERVIEW 70
9.2 CANCER STEM CELL RESEARCH 73
9.3 MULTIPLE CHROMOSOME ABNORMALITIES 73
9.4 OTHERS 74
10 GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER 75
10.1 OVERVIEW 76
10.2 RESEARCH & ACADEMIC INSTITUTES 79
10.3 REFERENCE LABORATORIES 79
10.4 HOSPITALS AND PHYSICIAN LABORATORIES 80
11 GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION 81
11.1 OVERVIEW 82
11.2 NORTH AMERICA 87
11.2.1 U.S. 93
11.2.2 CANADA 95
11.2.3 MEXICO 97
11.3 EUROPE 99
11.3.1 GERMANY 105
11.3.2 FRANCE 107
11.3.3 U.K. 109
11.3.4 ITALY 111
11.3.5 RUSSIA 113
11.3.6 SPAIN 115
11.3.7 TURKEY 117
11.3.8 NETHERLANDS 119
11.3.9 SWITZERLAND 121
11.3.10 BELGIUM 123
11.3.11 REST OF EUROPE 125
11.4 ASIA-PACIFIC 126
11.4.1 CHINA 132
11.4.2 JAPAN 134
11.4.3 INDIA 136
11.4.4 SOUTH KOREA 138
11.4.5 AUSTRALIA 140
11.4.6 SINGAPORE 142
11.4.7 THAILAND 144
11.4.8 MALAYSIA 146
11.4.9 INDONESIA 148
11.4.10 PHILIPPINES 150
11.4.11 REST OF ASIA-PACIFIC 152
11.5 SOUTH AMERICA 153
11.5.1 BRAZIL 158
11.5.2 ARGENTINA 160
11.5.3 REST OF SOUTH AMERICA 162
11.6 MIDDLE EAST AND AFRICA 163
11.6.1 SOUTH AFRICA 169
11.6.2 SAUDI ARABIA 171
11.6.3 U.A.E 173
11.6.4 EGYPT 175
11.6.5 ISRAEL 177
11.6.6 REST OF MIDDLE EAST AND AFRICA 179
12 GLOBAL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE 180
12.1 COMPANY SHARE ANALYSIS: GLOBAL 180
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 181
12.3 COMPANY SHARE ANALYSIS: EUROPE 182
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 183
13 SWOT ANALYSIS 184
14 COMPANY PROFILE 185
14.1 GUARDANT HEALTH 185
14.1.1 COMPANY SNAPSHOT 185
14.1.2 REVENUE ANALYSIS 185
14.1.3 COMPANY SHARE ANALYSIS 186
14.1.4 PRODUCT PORTFOLIO 186
14.1.5 RECENT DEVELOPMENTS 186
14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC) 188
14.2.1 COMPANY SNAPSHOT 188
14.2.2 REVENUE ANALYSIS 188
14.2.3 COMPANY SHARE ANALYSIS 189
14.2.4 PRODUCT PORTFOLIO 189
14.2.5 RECENT DEVELOPMENTS 189
14.3 FOUNDATION MEDICINE, INC. 190
14.3.1 COMPANY SNAPSHOT 190
14.3.2 COMPANY SHARE ANALYSIS 190
14.3.3 PRODUCT PORTFOLIO 191
14.3.4 RECENT DEVELOPMENTS 191
14.4 ILLUMINA, INC. 192
14.4.1 COMPANY SNAPSHOT 192
14.4.2 REVENUE ANALYSIS 192
14.4.3 COMPANY SHARE ANALYSIS 193
14.4.4 PRODUCT PORTFOLIO 193
14.4.5 RECENT DEVELOPMENT 193
14.5 NATERA, INC. 194
14.5.1 COMPANY SNAPSHOT 194
14.5.2 REVENUE ANALYSIS 194
14.5.3 COMPANY SHARE ANALYSIS 195
14.5.4 PRODUCT PORTFOLIO 195
14.5.5 RECENT DEVELOPMENT 195
14.6 BIO-RAD LABORATORIES, INC. 196
14.6.1 COMPANY SNAPSHOT 196
14.6.2 REVENUE ANALYSIS 196
14.6.3 PRODUCT PORTFOLIO 197
14.6.4 RECENT DEVELOPMENT 197
14.7 QIAGEN 198
14.7.1 COMPANY SNAPSHOT 198
14.7.2 REVENUE ANALYSIS 198
14.7.3 PRODUCT PORTFOLIO 199
14.7.4 RECENT DEVELOPMENTS 199
14.8 THERMO FISHER SCIENTIFIC INC. 200
14.8.1 COMPANY SNAPSHOT 200
14.8.2 REVENUE ANALYSIS 200
14.8.3 PRODUCT PORTFOLIO 201
14.8.4 RECENT DEVELOPMENTS 201
14.9 BIOCEPT, INC. 202
14.9.1 COMPANY SNAPSHOT 202
14.9.2 REVENUE ANALYSIS 202
14.9.3 PRODUCT PORTFOLIO 203
14.9.4 RECENT DEVELOPMENT 203
14.10 BIOLIDICS LIMITED 204
14.10.1 COMPANY SNAPSHOT 204
14.10.2 REVENUE ANALYSIS 204
14.10.3 PRODUCT PORTFOLIO 205
14.10.4 RECENT DEVELOPMENTS 205
14.11 EXACT SCIENCES CORPORATION 206
14.11.1 COMPANY SNAPSHOT 206
14.11.2 REVENUE ANALYSIS 206
14.11.3 PRODUCT PORTFOLIO 207
14.11.4 RECENT DEVELOPMENT 207
14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION) 208
14.12.1 COMPANY SNAPSHOT 208
14.12.2 REVENUE ANALYSIS 208
14.12.3 PRODUCT PORTFOLIO 209
14.12.4 RECENT DEVELOPMENTS 209
14.13 F. HOFFMANN-LA ROCHE LTD 210
14.13.1 COMPANY SNAPSHOT 210
14.13.2 RECENT FINANCIALS 210
14.13.3 PRODUCT PORTFOLIO 211
14.13.4 RECENT DEVELOPMENTS 211
14.14 IMMUCOR 212
14.14.1 COMPANY SNAPSHOT 212
14.14.2 PRODUCT PORTFOLIO 212
14.14.3 RECENT DEVELOPMENTS 212
14.15 INIVATA LTD 213
14.15.1 COMPANY SNAPSHOT 213
14.15.2 PRODUCT PORTFOLIO 213
14.15.3 RECENT DEVELOPMENTS 213
14.16 LUCENCE HEALTH, INC. 214
14.16.1 COMPANY SNAPSHOT 214
14.16.2 PRODUCT PORTFOLIO 214
14.16.3 RECENT DEVELOPMENTS 214
14.17 LUNGLIFE AI, INC. 215
14.17.1 COMPANY SNAPSHOT 215
14.17.2 PRODUCT PORTFOLIO 215
14.17.3 RECENT DEVELOPMENTS 215
14.18 MDXHEALTH 216
14.18.1 COMPANY SNAPSHOT 216
14.18.2 REVENUE ANALYSIS 216
14.18.3 PRODUCT PORTFOLIO 217
14.18.4 RECENT DEVELOPMENT 217
14.19 MENARINI SILICON BIOSYSTEMS 218
14.19.1 COMPANY SNAPSHOT 218
14.19.2 PRODUCT PORTFOLIO 218
14.19.3 RECENT DEVELOPMENTS 218
14.20 MYRIAD GENETICS, INC. 219
14.20.1 COMPANY SNAPSHOT 219
14.20.2 REVENUE ANALYSIS 219
14.20.3 PRODUCT PORTFOLIO 220
14.20.4 RECENT DEVELOPMENTS 220
14.21 VORTEX BIOSCIENCES 221
14.21.1 COMPANY SNAPSHOT 221
14.21.2 PRODUCT PORTFOLIO 221
14.21.3 RECENT DEVELOPMENTS 221
15 QUESTIONNAIRE 222
16 RELATED REPORTS 225
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
